Rhon-klinikum Ag · XETR:RHK
Rhon-klinikum — Non-Deal Roadshow (March 2015)
16 slides from Rhon-klinikum's roadshow presentation, March 2015
Slide 1: RHÖN-KLINIKUM AG Roadshow Presentation
RHÖN-KLINIKUM AG Roadshow Presentation March 2015
Slide 2: Content
Content 1 Preliminary Results for Financial Year 2014 2 Transformational Transcation and Share Repurchase RHÖN-KLINIKUM AG 2
Slide 3: Highlights FY 2014
Highlights FY 2014 Dominating event Comprehensive transformation at all levels Shareholder Structure as of 31 December 2014, according to the most recent of the year: March: closing of transaction with notifications of voting rights at that time execution of Fresenius/Helios and step-by-step 18.01%
Slide 4: Attractive Revenue Growth in Q4
Attractive Revenue Growth in Q4 Case numbers for new group Pro-forma revenues for new group* +7.8% +5.5% 690 in thsd. +5.2% in mio. € +49.1 +3.2% 680 270 +4.6% 270 670 677.8 267 268 660 260 262 650 +47.8 259 250 256 255 640 +1.3 251 630 620 628.7 240 610 600 230 FY 2013 ∆ inpatient ∆ outpatient FY 2
Slide 5: Key Events of Q4 2014
Key Events of Q4 2014 Conclusion of a turbulent year Closing and deconsolidation of the hospitals in Waltershausen-Friedrichroda and Boizenburg Net cash position end of December approx. € 540m P&L burdened by smaller one-off effects (e.g. IT services, share repurchase fees, revision of taxation for
Slide 6: Outlook FY 2015 and General Assumptions
Outlook FY 2015 and General Assumptions Expected average Growth still penalized by Expected input price Positive and negative organic growth regulation inflation one-time effects & KEY DRIVERS ASSUMPTIONS +3% to +4% p.a. 25% discount on agreed Wages +2.8 to +3.2% included Prices additional volumes w
Slide 7: Content
Content 1 Preliminary Results for Financial Year 2014 2 Transformational Transcation and Share Repurchase RHÖN-KLINIKUM AG 7
Slide 8: Review of a Transformational Transaction
Review of a Transformational Transaction PA S T S T R U C T U R E REVENUE POST-TRANSACTION New RHÖN Group (based on FY 2013 data) 2) FY 2013 RHÖN Portfolio − Cases 587k patients − Cases 2,654k patients − Revenues € ~ 1.020 ~ 1/3 − EBITDA € ~ 95m 1) − Revenues € 3,014m ~ 2/3 − Adj. EBITDA € ~ 310m 1)
Slide 9: Strong Position and Focus on High-End Medicine
Strong Position and Focus on High-End Medicine Revenues in FY 2013 .. …and tomorrow 1) 1,542 Helios ~ 3,4 Helios „neu“ ~ 5,5 +24% RHOEN ~ 3,0 Asklepios ~ 2,9 1,248 Asklepios ~ 2,9 Sana ~ 2,0 Sana ~ 2,0 RKA ~ 1,0 CMI 2) CMI 2) RKA „old“ RKA „new“ On average +24% higher complexity of cases in the new
Slide 10: Focus on High-End Medicine – Our New Portfolio in Detail (1/2)
Focus on High-End Medicine – Our New Portfolio in Detail (1/2) Bad Berka Bad Neustadt (Saale) Frankfurt (Oder) Revenue: ~ € 165m Revenue: ~ € 200m Revenue: ~ € 135m Key Facts * Beds: > 660 Beds: > 1,000 Beds: > 830 Patients treated: approx.. 43,000 Patients treated: approx. 46,000 Patients treated:
Slide 11: Focus on High-End Medicine – Our New Portfolio in Detail (2/2)
Focus on High-End Medicine – Our New Portfolio in Detail (2/2) UKGM Giessen-Marburg Bad Neustadt Frankfurt UKGM Bad Berka (Oder) Revenue: ~ € 570m Key Facts Beds: > 2,200 UKGM as reference center for scientific research and high-end Patients treated: c. 420,000 medicine at the university level withi
Slide 12: Share Repurchase: Successful Execution with Tradable Put Rights
Share Repurchase: Successful Execution with Tradable Put Rights Objectives of the share repurchase offer Tax efficient distribution of proceeds from Fresenius/HELIOS transaction Enabling a realignment of the shareholder base Offering attractive terms to shareholders while limiting the post deal impa
Slide 13: High Liquidity Both in Put rights and Share
High Liquidity Both in Put rights and Share Enabled Realignment of Shareholder Base Price and volume of tender rights Price and volume of share 1,65 2.800 25,00 1.800 Volume (RHS) Price tender right (LHS) Volume (RHS) Share price (LHS) 2.400 1,40 DD B. Braun 24,50 1.500 Melsungen Price tender right
Slide 14: Financial Calendar
Financial Calendar FY 2015 April 17, 2015 Press conference: publication of annual financial report 2014 May 7, 2015 Publication of interim report for the quarter ending March 31, 2015 June 10, 2015 Annual General Meeting (Jahrhunderthalle Frankfurt) August 6, 2015 Publication of the half year financ
Slide 15: Appendix: Price Regulation 2014/2015
Appendix: Price Regulation 2014/2015 Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Reference number: +2.53% (wage sum increase) RHÖN effective base rate Benchmark (wage sum) Layer 1 Sector-specific cost index was at +1
Slide 16: Disclaimer
Disclaimer • This document has been prepared by RHÖN-KLINIKUM AG (“RHÖN-KLINIKUM” or “the Company”) for information purposes only, solely for use at this presentation. It must be treated confidentially by attendees at such presentation and must not be distributed, passed on or otherwise disclosed. •